AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8888669 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty
Number of subjects: 0
Study 8888669 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 1345038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyruvate (36-53 g)
Number of subjects: 40
Study 1345038 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Polycose, 21-37 g)
Number of subjects: 40
Study 2863675 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol alone
Number of subjects: 748
Study 2863675 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol plus penicillin
Number of subjects: 748
Study 31288846 — intervention group
Group type: EXPERIMENTAL
Intervention: PECAN intervention (Participation Enabling CAre in Nursing)
Number of subjects: 129
Study 31288846 — intervention group
Group type: COMPARATOR
Intervention: Optimised standard care (control group)
Number of subjects: 129
Study 31662409 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity behaviour change intervention
Number of subjects: 0
Study 31662409 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation about physical activity
Number of subjects: 0
Study 26912731 — intervention group
Group type: EXPERIMENTAL
Intervention: QAR-Depression condition
Number of subjects: 51
Study 26912731 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 51
Study 26041131 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet recommendations plus free Smartphone application and wearable device
Number of subjects: 70
Study 26041131 — intervention group
Group type: COMPARATOR
Intervention: Standard diet recommendations alone
Number of subjects: 70
Study 23524063 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Functioning (EF) training with game-elements for 6 weeks
Number of subjects: 44
Study 23524063 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 44
Study 21681921 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy infused on days 0-3 and 8-17
Number of subjects: 289
Study 21681921 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (AML control group)
Number of subjects: 289
Study 19500616 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal distractor
Number of subjects: 0
Study 19500616 — intervention group
Group type: COMPARATOR
Intervention: Supraliminal distractor (control)
Number of subjects: 0
Study 16689038 — intervention group
Group type: EXPERIMENTAL
Intervention: Education, reminder system, and mechanical toothbrush
Number of subjects: 50
Study 16689038 — intervention group
Group type: COMPARATOR
Intervention: Mechanical toothbrush
Number of subjects: 50
Study 15568932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperatively assessed optical properties using spatially resolved diffuse remittance spectroscopy (DRS)
Number of subjects: 24
Study 11294480 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (reversible monoamine oxidase A inhibitor)
Number of subjects: 0
Study 11294480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9398716 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, three times daily for 4-6 weeks)
Number of subjects: 31
Study 9398716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7639379 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 10
Study 7639379 — intervention group
Group type: COMPARATOR
Intervention: Citrate (ACD)
Number of subjects: 10
Study 2906017 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol, 400 mg once daily
Number of subjects: 16
Study 2906017 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, 100 mg once daily
Number of subjects: 16
Study 29634375 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 52
Study 27148652 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries Classification System (CCS) training
Number of subjects: 8
Study 27148652 — intervention group
Group type: EXPERIMENTAL
Intervention: International Caries Detection and Assessment System (ICDAS II) training
Number of subjects: 8
Study 27148652 — intervention group
Group type: COMPARATOR
Intervention: Visual-tactile (VT) examination
Number of subjects: 8
Study 24684734 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (5 mg patch)
Number of subjects: 12
Study 24684734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23557068 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg udenafil + tamsulosin placebo
Number of subjects: 27
Study 23557068 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg udenafil + 0.4 mg tamsulosin
Number of subjects: 27
Study 23557068 — intervention group
Group type: COMPARATOR
Intervention: udenafil placebo + 0.4 mg tamsulosin
Number of subjects: 27
Study 21434580 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg) with buprenorphine placebo
Number of subjects: 45
Study 21434580 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (2 mg) with memantine placebo
Number of subjects: 45
Study 19887810 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic remedies (verum)
Number of subjects: 24
Study 19887810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19887810 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life, coping, global assessments of treatment success
Number of subjects: 24
Study 16501299 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 400
Study 16501299 — intervention group
Group type: COMPARATOR
Intervention: Non-amiodarone
Number of subjects: 400
Study 12740279 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 211
Study 12740279 — intervention group
Group type: COMPARATOR
Intervention: Surgical tracheostomy (ST)
Number of subjects: 211
Study 10770146 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in 1 tablet daily (n = 1380)
Number of subjects: 2763
Study 10770146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1383)
Number of subjects: 2763
Study 10770146 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and progestin
Number of subjects: 2763
Study 9301383 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 84.2 micrograms kg‐1
Number of subjects: 70
Study 9301383 — intervention group
Group type: COMPARATOR
Intervention: pancuronium 68.5 micrograms kg‐1
Number of subjects: 70
Study 8333822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 75
Study 8333822 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 75
Study 8333822 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 75
Study 8333822 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 3591595 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline hydrochloride 24 mg once a day for 4 weeks
Number of subjects: 95
Study 3591595 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline hydrochloride 12 mg once a day for 4 weeks
Number of subjects: 95
Study 3591595 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline hydrochloride (both dosages)
Number of subjects: 95
Study 28866315 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals of Care (GOC) decision aid intervention
Number of subjects: 11
Study 27016217 — intervention group
Group type: EXPERIMENTAL
Intervention: Flotation-REST treatment (12 sessions)
Number of subjects: 50
Study 27016217 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 50
Study 24608453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine with temozolomide and radiation therapy
Number of subjects: 24
Study 24608453 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide and radiation therapy (Control)
Number of subjects: 24
Study 23478632 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Disposable (DD) contact lenses
Number of subjects: 283
Study 23478632 — intervention group
Group type: COMPARATOR
Intervention: Daily Wear with Hydrogen Peroxide (DW-H2O2)
Number of subjects: 283
Study 23478632 — intervention group
Group type: COMPARATOR
Intervention: Daily Wear with Multipurpose Solutions (DW-MPS)
Number of subjects: 283
Study 16020461 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on a cycle ergometer for 60 min at 50% of peak oxygen consumption after a meal (M‐‐>E)
Number of subjects: 6
Study 16020461 — intervention group
Group type: COMPARATOR
Intervention: Resting conditions before and after a meal (M‐‐>R)
Number of subjects: 6
Study 16020461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of food intake and exercise
Number of subjects: 6
Study 16020461 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and food intake
Number of subjects: 6
Study 12559641 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lung cancer prevention agent (specifics not provided)
Number of subjects: 0
Study 12559641 — intervention group
Group type: EXPERIMENTAL
Intervention: Study vitamins (specifics not provided)
Number of subjects: 0
Study 12559641 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up activities planned for disease endpoints and smoking behavior
Number of subjects: 0
Study 9858113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (200 mg/day)
Number of subjects: 10
Study 9858113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9858113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (3 mg/day)
Number of subjects: 10
Study 7596966 — intervention group
Group type: EXPERIMENTAL
Intervention: State Modulation (SM) treatment
Number of subjects: 327
Study 7596966 — intervention group
Group type: COMPARATOR
Intervention: State Modulation (SM) combined with PHN or NSTEP‐P
Number of subjects: 327
Study 7596966 — intervention group
Group type: COMPARATOR
Intervention: State Modulation (SM) combined with NSTEP‐P
Number of subjects: 327
Study 2187001 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment (two different dosage regimens)
Number of subjects: 7
Study 2187001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 382149 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (30 mg/day)
Number of subjects: 41
Study 382149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 382149 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (30 mg/day) during open phase
Number of subjects: 41
Study 31297652 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 96
Study 31297652 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 96
Study 29278354 — intervention group
Group type: EXPERIMENTAL
Intervention: MiStent SES
Number of subjects: 148
Study 29278354 — intervention group
Group type: COMPARATOR
Intervention: Endeavor
Number of subjects: 148
Study 27475087 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of dasatinib once daily
Number of subjects: 79
Study 27475087 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg of dasatinib twice daily
Number of subjects: 79
Study 25129979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular NGF treatment
Number of subjects: 115
Study 25129979 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous vasodilators, energy mixture, steroid pulse therapy, methylcobalamin neurotrophic therapy)
Number of subjects: 115
Study 23715562 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE‐A3 immunotherapy with AS15
Number of subjects: 0
Study 23715562 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE‐A3 immunotherapy with AS02B
Number of subjects: 0
Study 23715562 — intervention group
Group type: COMPARATOR
Intervention: MAGE‐A3 plus AS02B in GS-positive patients
Number of subjects: 0
Study 23715562 — intervention group
Group type: COMPARATOR
Intervention: Placebo in GS-positive patients
Number of subjects: 0
Study 20135094 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (rhPTH (1‐34), TPTD) for 24 months
Number of subjects: 45
Study 18949181 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (500 mg/day) for 12 days
Number of subjects: 86
Study 18949181 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 days
Number of subjects: 86
Study 15843667 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (400 mg daily for 2 weeks, then 10-day course every month for 2 years)
Number of subjects: 4162
Study 15843667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4162
Study 15843667 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 4162
Study 15843667 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin and Placebo
Number of subjects: 4162
Study 12426647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt-table testing (TTT) performed in the afternoon first, then in the morning (Group I: 68 patients)
Number of subjects: 123
Study 12426647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt-table testing (TTT) performed in the morning first, then in the afternoon (Group II: 55 patients)
Number of subjects: 123
Study 12426647 — intervention group
Group type: COMPARATOR
Intervention: Tilt-table testing (TTT) performed in the afternoon
Number of subjects: 123
Study 12426647 — intervention group
Group type: COMPARATOR
Intervention: Tilt-table testing (TTT) performed in the morning
Number of subjects: 123
Study 12426647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt-table testing (TTT) with first negative tests
Number of subjects: 123
Study 12426647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt-table testing (TTT) with first positive tests
Number of subjects: 123
Study 10351964 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (bolus 0.25 mg/kg and 12-hour infusion of 0.125 microg/kg/min)
Number of subjects: 888
Study 10351964 — intervention group
Group type: COMPARATOR
Intervention: Accelerated-dose alteplase (100 mg)
Number of subjects: 888
Study 10351964 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (50 mg, 15 mg bolus; infusion of 35 mg over 60 minutes) plus abciximab
Number of subjects: 888
Study 10351964 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (50 mg, 15 mg bolus; infusion of 35 mg over 60 minutes) plus abciximab and low-dose heparin
Number of subjects: 888
Study 10351964 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (50 mg, 15 mg bolus; infusion of 35 mg over 60 minutes) plus abciximab and very-low-dose heparin
Number of subjects: 888
Study 10351964 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (500,000 U to 1.5 MU) plus abciximab
Number of subjects: 888
Study 10351964 — intervention group
Group type: COMPARATOR
Intervention: Alteplase alone (n=235)
Number of subjects: 888
Study 10351964 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab alone (n=32)
Number of subjects: 888
Study 10351964 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase plus abciximab (n=143)
Number of subjects: 888
Study 8824651 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (5 g b.d.)
Number of subjects: 22
Study 8824651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2117517 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐Ng, 0.03 mg twice a day for 20 days)
Number of subjects: 183
Study 2117517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE, 0.05 mg per day for 20 days)
Number of subjects: 183
Study 2117517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Ib, 800 mg three times a day for 5 days)
Number of subjects: 183
Study 2117517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, one pill of lactose for 20 days)
Number of subjects: 183
Study 7352687 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 0.1 mg
Number of subjects: 0
Study 7352687 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (various dosages)
Number of subjects: 0
Study 7352687 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 0.1 mg (repeated administration)
Number of subjects: 0
Study 30939422 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (Group S, n = 40) - 2 mg/kg
Number of subjects: 84
Study 30939422 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (Group N, n = 44) - 1 mg neostigmine methylsulfate and 0.2 mg glycopyrrolate
Number of subjects: 84
Study 28493338 — intervention group
Group type: EXPERIMENTAL
Intervention: gustatory event‐related potentials (gERPs) with five isointense basic tastants presented at a medium level
Number of subjects: 96
Study 28493338 — intervention group
Group type: EXPERIMENTAL
Intervention: gustatory event‐related potentials (gERPs)
Number of subjects: 96
Study 26091743 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based training on providing counselling and insertion of IUDs or progestin implants
Number of subjects: 1500
Study 26091743 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1500
Study 23504679 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser lithotripsy
Number of subjects: 112
Study 23504679 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic lithotripsy
Number of subjects: 112
Study 21691464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4mg
Number of subjects: 64
Study 21691464 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine 10mg
Number of subjects: 64
Study 20137622 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electro-resection as sole modality (investigation group)
Number of subjects: 48
Study 20137622 — intervention group
Group type: COMPARATOR
Intervention: Transurethral electro-resection or electric coagulation combined with bladder instillation of anti-tumor drugs (control group)
Number of subjects: 48
Study 17036169 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for stress urinary incontinence
Number of subjects: 655
Study 17036169 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and sociodemographic factors
Number of subjects: 655
Study 15056514 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.02-0.06 mg/kg/day, mean dose 1.5 mg/day)
Number of subjects: 107
Study 15056514 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 107
Study 11822756 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan followed by Etoposide (TE group: T on days 1-3 and E on days 4-6)
Number of subjects: 19
Study 11822756 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide followed by Topotecan (ET group: E on days 1-3 and T on days 4-6)
Number of subjects: 19
Study 11822756 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan and Etoposide (dose level 3: T/E 1.00/100 mg/m2 and 75 mg/m2 respectively)
Number of subjects: 19
Study 11822756 — intervention group
Group type: COMPARATOR
Intervention: Topotecan and Etoposide (TE and ET groups)
Number of subjects: 19
Study 9715339 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 36
Study 9715339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7974314 — intervention group
Group type: EXPERIMENTAL
Intervention: Education centre plus usual follow up
Number of subjects: 0
Study 7974314 — intervention group
Group type: COMPARATOR
Intervention: Usual follow up
Number of subjects: 0
Study 2604350 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous postoperative wound perfusion with 0.5% bupivacaine for 24 h followed by normal saline for a further 24 h
Number of subjects: 30
Study 2604350 — intervention group
Group type: COMPARATOR
Intervention: Normal saline perfusion
Number of subjects: 30
Study 1177348 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (trimethoprim/sulphamethoxazole, 10 mg trimethoprim/kg/day in two divided daily doses for 10 days)
Number of subjects: 23
Study 1177348 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (100 mg/kg/day in four divided daily doses for 10 days)
Number of subjects: 23
Study 29865924 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture or autologous cartilage implantation
Number of subjects: 16
Study 28607333 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 150
Study 28607333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 150
Study 28607333 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 150
Study 25372657 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem adaptation therapy (PATH)
Number of subjects: 74
Study 25372657 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy for cognitively impaired patients (ST‐CI)
Number of subjects: 74
Study 23444096 — intervention group
Group type: EXPERIMENTAL
Intervention: 5RM leg-press re-warm-up
Number of subjects: 0
Study 23444096 — intervention group
Group type: EXPERIMENTAL
Intervention: SSG re-warm-up
Number of subjects: 0
Study 23444096 — intervention group
Group type: COMPARATOR
Intervention: CON (passive recovery)
Number of subjects: 0
Study 21474499 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-detected emphysema severity (measured by Perc15)
Number of subjects: 2085
Study 19141981 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery first-ligation group (PA group)
Number of subjects: 26
Study 19141981 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein first-ligation group (PV group)
Number of subjects: 26
Study 19141981 — intervention group
Group type: EXPERIMENTAL
Intervention: NSCLC patients compared to benign lung disease and healthy persons
Number of subjects: 26
Study 19141981 — intervention group
Group type: EXPERIMENTAL
Intervention: NSCLC stage III and lymph node positive
Number of subjects: 26
Study 19141981 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal part of the pulmonary vein
Number of subjects: 26
Study 19141981 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperation vs. 7 days after operation
Number of subjects: 26
Study 16189291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (30 mg)
Number of subjects: 14
Study 16189291 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg)
Number of subjects: 14